Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul 2;56(1):2000627.
doi: 10.1183/13993003.00627-2020. Print 2020 Jul.

The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision

Collaborators, Affiliations
Editorial

The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision

Alexander G Mathioudakis et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.G. Mathioudakis reports grants from Boehringer Ingelheim, outside the submitted work. Conflict of interest: P. Sivapalan reports personal fees for lectures from Boehringer Ingelheim, outside the submitted work. Conflict of interest: A. Papi reports grants, personal fees for advisory board work, consultancy and lectures, and travel expenses reimbursement from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici and TEVA, personal fees for advisory board work, consultancy and lectures, and travel expenses reimbursement from Mundipharma, Zambon, Novartis and Sanofi/Regeneron, grants, personal fees for lectures, and travel expenses reimbursement Menarini, personal fees for advisory board work and consultancy, and travel expenses reimbursement from Roche, grants from Fondazione Maugeri and Fondazione Chiesi, personal fees for consultancy from Edmondpharma, outside the submitted work. Conflict of interest: J. Vestbo reports personal fees for advisory board work and lectures from AstraZeneca, grants and personal fees for lectures from Boehringer Ingelheim, personal fees for advisory board work and lectures from Chiesi and Novartis, personal fees for advisory board work from GSK, outside the submitted work; and has a family member who is employed by Chiesi.

Publication types

MeSH terms

Substances